NCT04883281View on ClinicalTrials.gov

A Prospective Study of Daily Adaptive Radiotherapy to Better Organ-at-Risk Doses in Head and Neck Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

February 23, 2022

Primary Completion Date

September 4, 2024

Study Completion Date

September 4, 2024

Conditions
Head and Neck Cancer
Interventions
RADIATION

Intensity modulated radiation therapy (IMRT) with or without chemotherapy

Intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel)

DRUG

cisplatin, cetuximab, or carboplatin-paclitaxel

chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel)

Trial Locations (1)

75390

University of Texas Southwestern Medical Center, Dallas

All Listed Sponsors
lead

University of Texas Southwestern Medical Center

OTHER